Susquehanna International Group
PTGX icon

Susquehanna International Group’s Protagonist Therapeutics PTGX Stock Holding History

Susquehanna International Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.99M Sell
57,062
-110,514
-66% -$11.5M ﹤0.01% 3997
2026
Q1 		$17.7M Buy
167,576
+155,814
+1,325% +$13.8M ﹤0.01% 2380
2025
Q4 		$1.03M Sell
11,762
-51,426
-81% -$4.21M ﹤0.01% 7130
2025
Q3 		$4.2M Sell
63,188
-8,053
-11% -$458K ﹤0.01% 4373
2025
Q2 		$3.94M Sell
71,241
-120,998
-63% -$5.81M ﹤0.01% 4419
2025
Q1 		$9.3M Buy
192,239
+122,302
+175% +$5.12M ﹤0.01% 2623
2024
Q4 		$2.7M Buy
69,937
+29,580
+73% +$1.29M ﹤0.01% 4673
2024
Q3 		$1.82M Sell
40,357
-315,229
-89% -$12.7M ﹤0.01% 5454
2024
Q2 		$12.3M Buy
355,586
+283,768
+395% +$8.31M ﹤0.01% 2231
2024
Q1 		$2.08M Sell
71,818
-37,865
-35% -$1.03M ﹤0.01% 5247
2023
Q4 		$2.52M Buy
109,683
+52,438
+92% +$917K ﹤0.01% 4897
2023
Q3 		$955K Buy
57,245
+41,281
+259% +$801K ﹤0.01% 6729
2023
Q2 		$441K Sell
15,964
-108,120
-87% -$2.71M ﹤0.01% 8597
2023
Q1 		$2.85M Buy
124,084
+57,053
+85% +$958K ﹤0.01% 4431
2022
Q4 		$731K Sell
67,031
-79,457
-54% -$670K ﹤0.01% 6904
2022
Q3 		$1.24M Buy
146,488
+81,328
+125% +$770K ﹤0.01% 6089
2022
Q2 		$516K Buy
65,160
+14,406
+28% +$174K ﹤0.01% 8174
2022
Q1 		$1.2M Sell
50,754
-245,659
-83% -$6.92M ﹤0.01% 6649
2021
Q4 		$10.1M Buy
296,413
+29,030
+11% +$918K ﹤0.01% 2692
2021
Q3 		$4.74M Buy
267,383
+246,050
+1,153% +$10.5M ﹤0.01% 4047
2021
Q2 		$957K Sell
21,333
-12,801
-38% -$423K ﹤0.01% 7897
2021
Q1 		$884K Buy
34,134
+13,781
+68% +$349K ﹤0.01% 8052
2020
Q4 		$410K Buy
20,353
+9,133
+81% +$197K ﹤0.01% 8687
2020
Q3 		$219K Buy
+11,220
New +$211K ﹤0.01% 9313
2019
Q2 		– Sell
-47,788
Closed -$601K – 10710
2019
Q1 		$601K Buy
47,788
+32,580
+214% +$288K ﹤0.01% 5928
2018
Q4 		$102K Buy
+15,208
New +$121K ﹤0.01% 8213

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Susquehanna International Group's PTGX Position: Q2 2026 in Review

Susquehanna International Group reduced its Protagonist Therapeutics (PTGX) stake by 66% in Q2 2026, selling an estimated $11.5M and leaving 57,062 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

Susquehanna International Group first reported a position in PTGX in Q4 2018 and has held it in 26 quarters since. The position peaked at $17.7M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Susquehanna International Group held 57,062 shares of Protagonist Therapeutics worth $6.99M as of Q2 2026.
  • Susquehanna International Group sold 110,514 Protagonist Therapeutics shares in Q2 2026, an estimated $11.5M.
  • Protagonist Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #3997 holding.
  • Susquehanna International Group first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 26 quarters since.
  • Susquehanna International Group's Protagonist Therapeutics position peaked at $17.7M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.